Immune Resilience Stack
Thymosin Alpha-1 + KPV + LL-37 - the immune-modulating combination users research for chronic low-grade inflammation.
About This Stack
The Immune Resilience Stack combines three peptides with immune-modulating mechanisms: Thymosin Alpha-1 (T-cell maturation signal), KPV (tripeptide with anti-inflammatory activity), and LL-37 (cathelicidin-class antimicrobial peptide). Each operates on a different immune axis, which is why they are commonly discussed together.
Users research this combination in the context of chronic low-grade inflammation, slow-to-heal infections, or gut-immune concerns. The compounds are all research-only in the US and require careful sourcing - quality and authenticity vary substantially in the gray market.
None of these compounds is presented as a treatment for any infection or autoimmune condition. Clinical immune dysfunction requires licensed medical evaluation.
Why These Compounds Are Researched Together
Thymosin Alpha-1 drives T-cell maturation and is approved in some countries for specific immune indications. KPV is the C-terminal tripeptide of alpha-MSH with documented anti-inflammatory effects on gut epithelium. LL-37 is the active form of cathelicidin (broad antimicrobial + immunomodulatory). The three mechanisms - T-cell signaling, epithelial anti-inflammation, antimicrobial activity - are distinct and complementary.
Compounds in the Immune Resilience Stack
Biomarkers Users Commonly Track
When running a stack like this, these biomarkers let users see how the compounds perform in context. Trended across draws, they reveal whether the stack is actually moving the markers it should - or producing unintended shifts that warrant a provider conversation.
Typical Cycle
Thymosin Alpha-1 cycles commonly run 3–6 months in community reports. KPV and LL-37 cycles vary by goal. All cycling decisions are a conversation with a licensed provider.
What to Discuss With Your Provider
Chronic inflammation has many causes (infection, autoimmunity, dental, sleep apnea). A workup with a licensed provider should precede any immune-modulating peptide research.
Log every compound in the stack, upload your lab PDFs, and chart the biomarkers on this page across every draw. StackAI reads the panel in context of what you’re running.
Start tracking free →